This study will be conducted in two parts. Part 1 of the study will test if the investigational drug, called loncastuximab tesirine in combination with rituximab, is a safe and effective treatment for DLBCL. Part 2 will compare the combination of loncastuximab tesirine with rituximab (Lonca-R) to a standard treatment regimen for DLBCL: rituximab plus gemcitabine and oxaliplatin (R-GemOx). The purpose of Part 2 is to evaluate whether Lonca-R is more effective than R-GemOx in decreasing the growth and spread of lymphoma, preventing it from coming back quickly and helping patients live longer.
Loncastuximab Tesirine with Rituximab vs Immunochemotherapy in DLBCL
OPEN TO ACCRUAL